Minerva Neurosciences Inc
Company Profile
Business description
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
Contact
1500 District Avenue
BurlingtonMA01803
USAT: +1 617 600-7373
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
8
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,510.70 | 43.70 | 0.52% |
CAC 40 | 7,873.83 | 23.73 | 0.30% |
DAX 40 | 23,638.56 | 72.02 | 0.31% |
Dow JONES (US) | 42,140.43 | 269.67 | -0.64% |
FTSE 100 | 8,602.92 | 2.06 | -0.02% |
HKSE | 23,108.27 | 441.19 | -1.87% |
NASDAQ | 19,010.09 | 301.74 | 1.61% |
Nikkei 225 | 38,183.26 | 539.00 | 1.43% |
NZX 50 Index | 12,781.20 | 5.54 | -0.04% |
S&P 500 | 5,886.55 | 42.36 | 0.72% |
S&P/ASX 200 | 8,269.00 | 35.50 | 0.43% |
SSE Composite Index | 3,374.87 | 5.63 | 0.17% |